London, UK, February 6, 2020 – To support medical researchers, policymakers, journalists and healthcare professionals in their efforts to better understand and combat coronavirus, now declared a global health emergency, we’ve assembled an array of valuable Clarivate resources.
Clarivate has proprietary data and insights spanning scientific and academic research, life sciences and intellectual property, which cover every stage of the fight against the coronavirus – from historical literature on all strains going back decades, to drug discovery and clinical development, regulatory submission, commercialization and patents.
Through our resource center, you can:
- Delve into the existing coronavirus drug research with 30 days of free access to the proprietary data in Cortellis Drug Discovery Intelligence, which is the broadest, deepest and most accurate source of R&D intelligence in one single platform; it includes data on drug pipelines, experimental pharmacology, pharmacokinetics, animal models, targets, patents and more.
- Access a free, comprehensive ‘disease briefing’ on Coronaviruses
- Read the top free papers on the Wuhan strain of the Coronavirus, carefully selected and curated from Web of Science, the only publisher-neutral database for original scientific literature
- Read the latest news and expert analysis on the coronavirus from BioWorld in real time as-it-happens. Coverage includes breaking research, clinical, regulatory and business development news, with archives on coronaviruses reaching back to 1991.
Amy Bourke-Waite, Director of External Communications, Clarivate Analytics
About Clarivate Analytics
Clarivate Analytics plc (NYSE:CCC; CCC.WS) is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. We have built some of the most trusted brands across the innovation lifecycle, including Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. Today, Clarivate Analytics™ is on a bold entrepreneurial mission to help our clients reduce the time from new ideas to life-changing innovations. For more information, please visit clarivate.com.
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements are more fully discussed under the caption “Risk Factors” in the prospectus as filed with the U.S. Securities and Exchange Commission (“SEC”) on September 9, 2019 (File No. 333-233590), along with our other filings with the SEC. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.
Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.